Circulating Biomarkers for Prediction of Objective Response to Chemotherapy in Pancreatic Cancer Patients
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Circulating Biomarkers for Prediction of Objective Response to Chemotherapy in Pancreatic Cancer Patients
Authors
Keywords
-
Journal
Cancers
Volume 11, Issue 1, Pages 93
Publisher
MDPI AG
Online
2019-01-16
DOI
10.3390/cancers11010093
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer
- (2018) Jin-Young Jang et al. ANNALS OF SURGERY
- The Systemic-Immune-Inflammation Index Independently Predicts Survival and Recurrence in Resectable Pancreatic Cancer and its Prognostic Value Depends on Bilirubin Levels
- (2018) Mohammad Hosein Aziz et al. ANNALS OF SURGERY
- HALO-109–301: a Phase III trial of PEGPH20 (with gemcitabine and nab-paclitaxel) in hyaluronic acid-high stage IV pancreatic cancer
- (2018) Gary J Doherty et al. Future Oncology
- Unicancer GI PRODIGE 24/CCTG PA.6 trial: A multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas.
- (2018) Thierry Conroy et al. JOURNAL OF CLINICAL ONCOLOGY
- Reproducibility of European Association for the Study of the Liver criteria and modified Response Evaluation Criteria in Solid Tumors in patients treated with sorafenib
- (2018) Mi Young Jeon et al. LIVER INTERNATIONAL
- MutantKRASCirculating Tumor DNA Is an Accurate Tool for Pancreatic Cancer Monitoring
- (2018) Ruth Perets et al. ONCOLOGIST
- Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma
- (2018) Janet E. Murphy et al. JAMA Oncology
- FOLFIRINOX Chemotherapy in Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis of Retrospective and Phase II Studies
- (2018) Stephane Thibodeau et al. Journal of Clinical Medicine
- Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study)
- (2018) Lilian Schwarz et al. BMC CANCER
- PRIMUS-001: An adaptive phase II study of FOLFOX-A (FOLFOX and nab-paclitaxel) versus AG (nab-paclitaxel and gemcitabine) in patients with metastatic pancreatic cancer, with integrated biomarker evaluation (ISRCTN75002153) – Part of Precision-Panc.
- (2018) Janet Shirley Graham et al. JOURNAL OF CLINICAL ONCOLOGY
- Analysis of ctDNA to predict prognosis and monitor treatment responses in metastatic pancreatic cancer patients
- (2017) He Cheng et al. INTERNATIONAL JOURNAL OF CANCER
- The Neutrophil/Lymphocyte Ratio at Diagnosis Is Significantly Associated with Survival in Metastatic Pancreatic Cancer Patients
- (2017) Matteo Piciucchi et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Circulating interleukin-18 (IL-18) is a predictor of response to gemcitabine based chemotherapy in patients with pancreatic adenocarcinoma
- (2017) Çiğdem Usul Afsar et al. JOURNAL OF INFECTION AND CHEMOTHERAPY
- Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial
- (2017) John P Neoptolemos et al. LANCET
- Effect of Neoadjuvant Nab-Paclitaxel plus Gemcitabine Therapy on Overall Survival in Patients with Borderline Resectable Pancreatic Cancer: A Prospective Multicenter Phase II Trial (NAC-GA Trial)
- (2017) Ken-ichi Okada et al. ONCOLOGY
- Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial - 1 (NorPACT-1)) – study protocol for a national multicentre randomized controlled trial
- (2017) Knut Jørgen Labori et al. BMC Surgery
- Circulating cell-free DNA mutation patterns in early and late stage colon and pancreatic cancer
- (2017) Eveline E. Vietsch et al. Cancer Genetics
- lncRNA MALAT1, HOTTIP and PVT1 as predictors for predicting the efficacy of GEM based chemotherapy in first-line treatment of pancreatic cancer patients
- (2017) Cui-Juan Wang et al. Oncotarget
- Neutrophil/lymphocyte ratio is a more sensitive systemic inflammatory response biomarker than platelet/lymphocyte ratio in the prognosis evaluation of unresectable pancreatic cancer
- (2017) Yuan Gao et al. Oncotarget
- Survival outcome and prognostic factors of neoadjuvant treatment followed by resection for borderline resectable pancreatic cancer
- (2017) Hyeong Seok Kim et al. Annals of Surgical Treatment and Research
- Evolving treatment landscape for early and advanced pancreatic cancer
- (2017) Sally C Lau et al. World Journal of Gastrointestinal Oncology
- Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer
- (2017) Marzia Del Re et al. Scientific Reports
- CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weeklynab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer
- (2016) E. G. Chiorean et al. ANNALS OF ONCOLOGY
- Prognostic value of circulating tumour DNA in patients undergoing curative resection for pancreatic cancer
- (2016) Naoto Hadano et al. BRITISH JOURNAL OF CANCER
- FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis
- (2016) Mustafa Suker et al. LANCET ONCOLOGY
- Long Noncoding RNA MALAT1 Promotes Aggressive Pancreatic Cancer Proliferation and Metastasis via the Stimulation of Autophagy
- (2016) L. Li et al. MOLECULAR CANCER THERAPEUTICS
- Potential predictive role of chemotherapy-induced changes of soluble CD40 ligand in untreated advanced pancreatic ductal adenocarcinoma
- (2016) Nicola Silvestris et al. OncoTargets and Therapy
- Circulating biomarkers to monitor cancer progression and treatment
- (2016) Suthee Rapisuwon et al. Computational and Structural Biotechnology Journal
- Circulating tumor cells (CTC) and KRAS mutant circulating free DNA (cfDNA) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer
- (2015) Julie Earl et al. BMC CANCER
- Circulating Tumor Cells and Circulating Tumor DNA: Challenges and Opportunities on the Path to Clinical Utility
- (2015) M. Ignatiadis et al. CLINICAL CANCER RESEARCH
- Biomarker: Predictive or Prognostic?
- (2015) Karla V. Ballman JOURNAL OF CLINICAL ONCOLOGY
- The long non-coding RNA HOTTIP promotes progression and gemcitabine resistance by regulating HOXA13 in pancreatic cancer
- (2015) Zhihua Li et al. Journal of Translational Medicine
- Clinical relevance of circulating KRAS mutated DNA in plasma from patients with advanced pancreatic cancer
- (2015) Kjersti Tjensvoll et al. Molecular Oncology
- Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
- (2014) L. Rahib et al. CANCER RESEARCH
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
- (2014) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Neoadjuvant FOLFIRINOX for Borderline Resectable Pancreas Cancer: A New Treatment Paradigm?
- (2014) K. K. Christians et al. ONCOLOGIST
- A Bayesian Meta-Analysis of Multiple Treatment Comparisons of Systemic Regimens for Advanced Pancreatic Cancer
- (2014) Kelvin Chan et al. PLoS One
- Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer
- (2014) Henriette Golcher et al. STRAHLENTHERAPIE UND ONKOLOGIE
- Overexpression of long non-coding RNA MALAT1 is correlated with clinical progression and unfavorable prognosis in pancreatic cancer
- (2014) Er-Jun Pang et al. TUMOR BIOLOGY
- Cytokeratin 19-fragments (CYFRA 21-1) as a novel serum biomarker for response and survival in patients with advanced pancreatic cancer
- (2013) S Boeck et al. BRITISH JOURNAL OF CANCER
- Role of the immune system in pancreatic cancer progression and immune modulating treatment strategies
- (2013) K. Sideras et al. CANCER TREATMENT REVIEWS
- Circulating nucleosomes and immunogenic cell death markers HMGB1, sRAGE and DNAse in patients with advanced pancreatic cancer undergoing chemotherapy
- (2013) Christin Wittwer et al. INTERNATIONAL JOURNAL OF CANCER
- Soluble receptor of advanced glycation end products (sRAGE) indicates response to chemotherapy in pancreatic cancer patients
- (2013) Christin Wittwer et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Monitoring of CA19-9 and SPan-1 can facilitate the earlier confirmation of progressing pancreatic cancer during chemotherapy
- (2013) Koichiro Tsutsumi et al. PANCREATOLOGY
- Pathology and Molecular Genetics of Pancreatic Neoplasms
- (2012) Laura D. Wood et al. CANCER JOURNAL
- Effect of Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid or Gemcitabine vs Observation on Survival in Patients With Resected Periampullary Adenocarcinoma
- (2012) John P. Neoptolemos et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Intra- and inter-observer variability in measurement of target lesions: implication on response evaluation according to RECIST 1.1
- (2012) Daniela Muenzel et al. Radiology and Oncology
- Potential plasticity of T regulatory cells in pancreatic carcinoma in relation to disease progression and outcome
- (2012) BARBARA VIZIO et al. Experimental and Therapeutic Medicine
- Genome-wide screen identifies PVT1 as a regulator of Gemcitabine sensitivity in human pancreatic cancer cells
- (2011) Lei You et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Pretreatment Carbohydrate Antigen 19-9 Level Indicates Tumor Response, Early Distant Metastasis, Overall Survival, and Therapeutic Selection in Localized and Unresectable Pancreatic Cancer
- (2011) Tae Yoo et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Carcinoembryonic antigen (CEA) as tumor marker in lung cancer
- (2011) M. Grunnet et al. LUNG CANCER
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- High-mobility group box 1 and cancer
- (2010) Daolin Tang et al. Biochimica et Biophysica Acta-Gene Regulatory Mechanisms
- Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer
- (2010) Motofumi Tanaka et al. CANCER
- Dynamic Behavior and Function of Foxp3+ Regulatory T Cells in Tumor Bearing Host
- (2010) F Xiao-Feng Qin Cellular & Molecular Immunology
- Significant Associations of Mismatch Repair Gene Polymorphisms With Clinical Outcome of Pancreatic Cancer
- (2009) Xiaoqun Dong et al. JOURNAL OF CLINICAL ONCOLOGY
- Long non-coding RNAs: insights into functions
- (2009) Tim R. Mercer et al. NATURE REVIEWS GENETICS
- Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study
- (2008) B. Chauffert et al. ANNALS OF ONCOLOGY
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- CA 19-9 as a Predictor for Response and Survival in Advanced Pancreatic Cancer Patients Treated With Chemoradiotherapy
- (2008) Woong Sub Koom et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started